Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2002, Pages 472-477

  Martin, Paul D ^a   Mitchell, Patrick D ^a   Schneck, Dennis W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

HMG CoA reductase; LDL C; Morning evening dosing; Rosuvastatin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TIME FACTORS;

EID: 0036432991     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01688.x     Document Type: Article

References (26)

1. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19: 187-195.
2. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341: 498-511.
3. Rubenfire M, Coletti AT, Mosca L. Treatment strategies for management of serum lipids: Lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. Prog Cardiovasc Dis 1998;41: 95-116.
4. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343: 425-430.
5. Aguilar-Salinas CA, Barrett H, Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis 1998;141: 203-207.
6. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: A look back and a look ahead. Can J Cardiol 1992; 8: 843-864.
7. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32: 403-425.
8. Parker TS, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: Relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 1982;79: 3037-3041.
9. Jones PJ, Schoeller DA. Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res 1990;31: 667-673.
10. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87(Suppl): III45-53.
11. Illingworth DR. Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther 1986;40: 338-343.
12. Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Atherosclerosis 1990;85: 219-227.
13. Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991;11: 816-826.
14. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504-508.
15. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89: 268-275.
16. Paoletti R, Fahmy M, Mahla G, Caplan R, Raza A. Rosuvastatin is more effective than pravastatin or simvastatin at improving the lipid profiles of hypercholesterolaemic patients. Atherosclerosis 2001; 2(Suppl 2): 87 ((Abstract) P164).
17. Stein EA, Strutt KL, Miller E, Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 2001;2(Suppl 2): 90 ((Abstract) P176).
18. Hunninghake DB, Chitra RR, Simonson SG, Schneck DW. Treatment of hypertriglyceridemic patients with rosuvastatin. Diabetes 2001;50(Suppl 2): 143 ((Abstract) 574P).
19. Warwick MJ, Dane AL, Raza A, Schneck DW. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 2000;151: 39 ((Abstract) MoP19: W6).
20. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin - a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; in press.
21. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifugation. Clin Chem 1972;18: 499-502.
22. Abrar M, Martin PD. Validation and application of an assay for the determination of mevalonic acid in human plasma by liquid chromatography tandem mass spectrometry. J Chromatogr B; 2002;773: 103-111.
23. Woollen BH, Holme PC, Northway WJ, Martin PD. Determination of mevalonic acid in human urine as mevalonic acid lactone by gas chromatography-mass spectrometry. J Chromatogr B 2001;760: 179-184.
24. Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B; 2002;772: 219-228.
25. Widerlöv E, Jostell KG, Claesson L, et al. Influence of food intake on electrocardiograms of healthy male volunteers. Eur J Clin Pharmacol 1999;55: 619-624.
26. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36: 604-609.